Αρχική World News 38% of Recurrent Breast Cancers Have a Different HER2 Status than the...

38% of Recurrent Breast Cancers Have a Different HER2 Status than the Primary Cancer

Breast cancers are often classified as either HER2-negative or HER2-positive, which helps doctors know what the best options are for the treatment of that specific type of cancer. However, new research suggests that nearly 40 percent of patients with a recurrent breast cancer case will have a different HER2 status than they had with their primary cancer diagnosis.

The human epidermal growth factor receptor 2 gene (HER2) normally helps control how a healthy breast cell grows, divides, and repairs itself. In about 10 to 20 percent of breast cancers, however, HER2 makes too many copies of itself (known as gene amplification). All those extra HER2 genes then cause breast cells to make too many HER2 receptors (known as protein overexpression), forcing breast cells to grow and divide uncontrollably.

Photo: Adobe Stock/David A Litman

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

Breast cancers that have HER2 gene amplification or HER2 protein overexpression are known as HER2-positive and tend to be more aggressive than other types of breast cancer. They are often treated using drugs that specifically target the HER2 protein.

Because a cancer patient’s HER2 status determines what treatments will be most effective for them, it’s vital for most patients with invasive breast cancer to find out what their HER2 status is. And new research is showing that it’s also important to get your HER2 status retested if you get a recurrent cancer case after your primary cancer has already been treated.

Photo: Adobe Stock/focusandblur

For the study, the researchers analyzed both the primary and secondary tumors of 575 patients who had recurrent breast cancer. Overall, they discovered that 38 percent of recurrent breast cancers had a different HER2 status than their primary cancers.

15 percent of HER2-negative primary breast cancers switched to HER2-low recurrent breast cancers (meaning the HER2 proteins present were elevated but not high enough to warrant a “positive” HER2 diagnosis). 14 percent of HER2-low primary breast cancers switched to HER2-negative recurrent breast cancers. And nine percent of the recurrent cancers either became HER2-positive or were not HER2-positive anymore.

The rate of HER2 status switching was highest among those whose original diagnosis was hormone-receptor-positive and HER2-negative.

Photo: Adobe Stock/arcyto

“The results provide a whole new insight on how HER2-low tumors might evolve as a subgroup, possibly challenging the current dichotomy between HER2-positive and HER2-negative breast cancer,” says Federica Miglietta, M.D., of the University of Padova, who presented the research, in a statement. “Our findings stress the importance of re-testing HER2 expression on tumor relapse since it might provide the option of new therapeutic opportunities, currently in a trial, and hopefully in the near future, in the clinic.”

So if you’ve had breast cancer before and you happen to develop it again, please don’t automatically assume that your new tumor will be the same HER2 status as your prior one was. If you doctor doesn’t order a new test for HER2 status and other biomarkers, request one so that you know you’ll be getting the best care possible for your individual case.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...